Skip to content
Evigrade
CriticalSelective serotonin 5HT1B/1D agonists (triptans)×Reversible MAO-A inhibitor (RIMA)

Updated · Methodology

Mechanism

Moclobemide reversibly inhibits monoamine oxidase (MAO), mainly type A, and slows the breakdown of serotonin, noradrenaline and dopamine (moclobemide summary of product characteristics, SmPC, section 5.1). Almotriptan is a selective agonist of the serotonin 5-HT1B and 5-HT1D receptors. Its main metabolic route is oxidative deamination by MAO type A, and cytochrome P450 (CYP3A4 and CYP2D6) enzymes and flavin monooxygenase also take part (almotriptan SmPC, sections 5.1 and 5.2). The moclobemide SmPC contraindicates triptans as potent serotonin receptor agonists whose plasma concentrations rise with moclobemide (section 4.5). In a study, moclobemide 150 mg twice daily for 8 days reduced almotriptan clearance by 27% and raised its peak concentration by about 6%. No dose adjustment is necessary (almotriptan label, US Food and Drug Administration, FDA, section 12.3). Among CYP enzymes, the moclobemide SmPC names moclobemide as an inhibitor of CYP2C19 only (section 4.5), and the almotriptan SmPC does not name this enzyme in almotriptan metabolism (section 5.2).

Symptoms

The documents do not describe how this particular combination presents, because the moclobemide summary of product characteristics (SmPC) contraindicates it in advance (sections 4.3 and 4.5). The Spanish almotriptan SmPC does not rule out serotonin syndrome from a pharmacodynamic interaction with monoamine oxidase inhibitors (section 4.5). Its signs are mental status changes, autonomic instability, neuromuscular changes and gastrointestinal symptoms (moclobemide SmPC, section 4.4). Examples are agitation, hallucinations, fast heart rate, labile blood pressure, high temperature, hyperreflexia, poor coordination, nausea, vomiting and diarrhoea (almotriptan label, US Food and Drug Administration, FDA, section 5.5). Almotriptan itself can cause a transient, moderate rise in blood pressure, more marked in older people. It can also cause chest pain or tightness that may be intense and spread to the throat (almotriptan SmPC, section 4.4).

Management

The combination is contraindicated. The moclobemide summary of product characteristics (SmPC) lists triptans among contraindicated drugs and names almotriptan explicitly (moclobemide SmPC, sections 4.3 and 4.5). The almotriptan documents are softer. The Spanish SmPC only states that a risk of serotonin syndrome with monoamine oxidase (MAO) inhibitors cannot be excluded (section 4.5). The US Food and Drug Administration (FDA) label does not list MAO inhibitors among its contraindications and, after a study with moclobemide, states that no almotriptan dose adjustment is necessary (sections 4 and 12.3). The strictest document prevails, so do not prescribe almotriptan to people taking moclobemide. No document gives an interval between stopping one drug and starting the other. If the two drugs have nevertheless been taken together and serotonin syndrome is suspected, the moclobemide SmPC advises considering a lower moclobemide dose or stopping it, depending on how severe the symptoms are (section 4.4). If chest pain or tightness occurs after almotriptan, withhold further doses and assess the patient (almotriptan SmPC, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Almotriptan

Other interactions with Moclobemide